Member Info for Celtic007

I won't take 15p......nono wayyyyh. We have got alacarte pharmaceutical drug menu......especially after yesterday news of chk1 excitement by board.....the most they have ever.......that alone is more than 15p

Now add in 2 tyk2 ....clear, safe and good.....28p looks rubbish.......

Ohhhhh add in covid19 possible treatment capsules......and 15p not on your nelly!!!

Bobby.....not really. A takeover would happen at the price the company think it is worth......A +B+C=D

The company sareum determines it, not the market.....lots of takeovers of multiples of current price....
Once in limelight....then other piranha can smell blood and you have a fight ....

So takeover bring it on.....still not get it cheap......why Lth here and board,who have repeated showcased other similar deals.....as am sure HWWI are there ....

So a company that took our flt3 and tried it and give it back but bought into sareum. Speaks volumes......woww.

THEY LIKED WHAT THEY SAW AND THE POTENTIAL REWARDS. ONLY TYK2 AVAILABLE TO LICENCE AND THE MOST CLEAN!!!

CHK1 I THINK WILL BE THE BIGGEEEEE...AS WE LTH ALWAYS THOUGHT

Yes you cannot buy or sell as a director...especially if TO made

https://www.fool.co.uk/2021/10/29/3-penny-stocks-id-aim-to-hold-for-10-years/

I think that we have more than enough to take care of without flt. 100 tumour regression with combo.....wow.....amazing....

I am not surprised with chk1 combo data nor are any other long term holders.....the data has shown that again.

Agree T/o will only happen if offer good....otherwise get the patents in place .

ONLY TYK2 AVAILBLE TO LICENCE IN THE WHOLE WORLD!!! THINK ABOUT THAT!!!

I think GSK as they are under real pressure to perform , especially as astra zeneca is doing amazing.

I am sure we are on the rader of lots of companies.....and the subram9ne patents and hwi on board will ensure that true value is reflected and still plenty left on the bones for the aquire.

If I was a big boy.....take the lot.....then you have all the goodies.....to yourself .

THE LONGER THEY DONT MAKE A MOVE, THE MORE OTHER INTERESRED PARTIES GET THE KNOW AND THE MORE EXPENSIVE IT GETS.

THIS NEW HIGHLY REGARDED BROKER NOE BOARD AM SURE HAS COME ON FROM ONE OF OUR HWI. IN THIS FIELD YOU WANT PAUL POGBA AGENT, SONEONE AMAZING AT GEYTING HIGH VALUE, AS GOT CONTACTS

Yep.agree.....as thoth said years ago tyk2 was the baby!!! The board not putting subramine patents in for no reason.....they want to milk this cow.....all teats.....not just one orctwo!!! Cowabunga!!!

Thank you hotblack

A question for all well educated....

This subramine patent is unique.....how often is this used in industry.? I would say hardly, unless you have a drug with multiple indications......

Am I correct?

I am so intrigued by this subramine patent as it shows that sareum will not let go of the golden goose cheaply. Quite beautiful, you design a beautiful drug and then onlicemse it to other big pharnmas for different multi million or bullion markets and sit back and benefit.

Like having a amazing horse stud, and you rent it out for its sperms, as very good chance that it too will be anazing.....

These guys know what they have, and will make sure that investors like us are well rewarded ......Nice to see that.

Tyk2 is the next hotie.....we are the only ones to licence

That post that steady said on advn
>>>>Silvergreyhead I think it is significant in a few respects, for example: 1) It will extend the IP for their preferred TYK2 inhibitor by about 3.5 years. The priority date for Sareum's original composition of matter patent application for the molecule was 21 October 2016 by the looks of it, the priority data for the new application is 07 April 2020. 2) The international search report cites only 2 examples of relevant prior art, that is two patent applications both assigned to Sareum - this should ensure that the new application satisfies the novelty criteria required for patent grant. 3) The application provides x-ray data for the new crystalline form - this is usually sufficient to satisfy the non-obvious criteria required for patent grant. So, what would an additional extra 3.5 years of exclusivity be be worth to a big pharma partner if the compound were a commercial success? I suspect the answer would be measured in billions rather than million of dollars. So all things

Ho thoth. Hope yiu are OK. More and more people want to join our chk1 party it seems

Wot a sidiasaster

Thanks steady

OK thank you. So you like thoth think they could have invested in sareum and be one of hnwi? Thanks and sorry not getting it

Hi steady. This post are you suggesting that GSk links ....a bit confused.

Beautiful summary krone

It is quite amazing to think we are only chk1 drug in this field.....look at all the runners to start off with and we have got rid of them. Sareum will be on the giants rader, as we other few runners that are going to shock the market big boys. Don't play up boys, but pay up, as every day you don't make a offer, the price goes up substantialy as the prices start fitting together like a complicated jigsaw.

I lost my dad to cancer and the fact a drug is out there that cod save lives is being ignored because of nonsense......love to see Sierra fold ........